166 related articles for article (PubMed ID: 37715962)
1. Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability.
Heneghan LJ; Tsang A; Dimino C; Khandji AG; Panigrahi SK; Page-Wilson G
J Clin Endocrinol Metab; 2024 Jan; 109(2):e667-e674. PubMed ID: 37715962
[TBL] [Abstract][Full Text] [Related]
2. Changes in the prolactin serum isoforms secreted by a pituitary adenoma associated with therapy.
Morán C; Tena G; Fonseca ME; Ochoa R; Bermúdez JA; Zárate A
Arch Med Res; 1994; 25(1):1-3. PubMed ID: 8019107
[TBL] [Abstract][Full Text] [Related]
3. Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma.
Hong JW; Lee MK; Kim SH; Lee EJ
Endocrine; 2010 Feb; 37(1):140-7. PubMed ID: 20963563
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic evaluation of hyperprolactinemia.
Biller BM
J Reprod Med; 1999 Dec; 44(12 Suppl):1095-9. PubMed ID: 10649817
[TBL] [Abstract][Full Text] [Related]
5. Drug treatment of hyperprolactinemia.
Chanson P; Borson-Chazot F; Chabre O; Estour B
Ann Endocrinol (Paris); 2007 Jun; 68(2-3):113-7. PubMed ID: 17532288
[TBL] [Abstract][Full Text] [Related]
6. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of ropinirole in patients with prolactinomas.
Liu S; Hu C; Peters J; Tsang A; Cremers S; Bies R; Page-Wilson G
Br J Clin Pharmacol; 2019 Feb; 85(2):366-376. PubMed ID: 30362146
[TBL] [Abstract][Full Text] [Related]
8. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
[TBL] [Abstract][Full Text] [Related]
9. Prolactin responsiveness to TRH in amenorrheic women with and without galactorrhea.
MacGregor C; Maldonado D; Canales ES; Soria J; Zárate A
Acta Obstet Gynecol Scand; 1977; 56(4):333-6. PubMed ID: 414510
[TBL] [Abstract][Full Text] [Related]
10. Guidelines for the diagnosis and treatment of hyperprolactinemia.
Biller BM; Luciano A; Crosignani PG; Molitch M; Olive D; Rebar R; Sanfilippo J; Webster J; Zacur H
J Reprod Med; 1999 Dec; 44(12 Suppl):1075-84. PubMed ID: 10649814
[TBL] [Abstract][Full Text] [Related]
11. Cabergoline in the long-term therapy of hyperprolactinemic disorders.
Ferrari C; Paracchi A; Mattei AM; de Vincentiis S; D'Alberton A; Crosignani P
Acta Endocrinol (Copenh); 1992 Jun; 126(6):489-94. PubMed ID: 1642081
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
13. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
14. [Effects of therapy and pregnancy on hyperprolactemia caused by a pituitary adenoma. A clinical case].
Pasinetti E; Schivardi MR; Falsetti L; Gastaldi A
Minerva Ginecol; 1989 Mar; 41(3):157-60. PubMed ID: 2666885
[TBL] [Abstract][Full Text] [Related]
15. [Current diagnosis and treatment of hyperprolactinemia].
Melgar V; Espinosa E; Sosa E; Rangel MJ; Cuenca D; Ramírez C; Mercado M
Rev Med Inst Mex Seguro Soc; 2016; 54(1):111-21. PubMed ID: 26820213
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of women with amenorrhea-galactorrhea treated with bromocriptine.
Tartagni M; Nicastri PL; Diaferia A; Di Gesù I; Loizzi P
Clin Exp Obstet Gynecol; 1995; 22(4):301-6. PubMed ID: 8777784
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia.
Lamberts SW; Quik RF
J Clin Endocrinol Metab; 1991 Mar; 72(3):635-41. PubMed ID: 1997518
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
19. A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients.
De Luis DA; Becerra A; Lahera M; Botella JI; Valero ; Varela C
J Endocrinol Invest; 2000; 23(7):428-34. PubMed ID: 11005266
[TBL] [Abstract][Full Text] [Related]
20. CV 205-502--effectiveness, tolerability, and safety over 24-month study.
Shoham Z; Homburg R; Jacobs HS
Fertil Steril; 1991 Mar; 55(3):501-6. PubMed ID: 1672113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]